Targets › CYP21A2
1 program from 1 company in 1 trial: 1 Phase 1; Genitourinary; next expected readout Feb 2029.
A cytochrome P450 monooxygenase that plays a major role in adrenal steroidogenesis. Catalyzes the hydroxylation at C-21 of progesterone and 17alpha-hydroxyprogesterone to respectively form 11-deoxycorticosterone and 11-deoxycortisol, intermediate metabolites in the biosynthetic pathway of mineralocorticoids and glucocorticoids. (UniProt, P08686)
Open in Phaseline: the race on CYP21A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Adrenas Therapeutics | AAV BBP-631 AAV5-mediated gene therapy delivering CYP21A2 | CYP21A2 | Phase 1 | Congenital Adrenal Hyperplasia | Feb 2029 |
Congenital Adrenal Hyperplasia (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.